MetaCap

Schrodinger (SDGR) vs Zenas BioPharma (ZBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Schrodinger (SDGR) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 39.2% versus a loss of 33.4%. Schrodinger is the larger company by market cap ($1.72 billion vs $1.62 billion), about 1.1 times the size, while Zenas BioPharma is growing revenue faster (+100.0% vs +23.3%). Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -3777.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SDGR+39.22%ZBIO-33.38%
+111%+23%-66%
Nov 21, 20251 yearNov 20, 2026
SDGR+10.61%ZBIO+31.40%
+144%+36%-71%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SDGR versus ZBIO key metrics
MetricSDGRZBIO
Share price$22.93$23.85
Market cap$1.72B$1.62B
1-day change-12.95%-4.75%
YTD return+28.24%-34.32%
1-year return+39.22%-33.38%
5-year return-42.01%—
EPS (TTM)$-0.79$-9.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$255.87M$10.00M
Revenue growth (YoY)+23.29%+100.00%
Net income (latest FY)$-103.27M$-377.74M
Gross margin55.74%—
Operating margin-65.23%-3830.57%
Net margin-40.36%-3777.37%
52-week high$34.00$44.60
52-week low$10.95$13.50
Distance from 52-week high-32.56%-46.52%
Analyst consensusbuystrong_buy
Avg. price target upside+46.40%+100.75%
Average volume2.08M593.08K
Shares outstanding65.91M67.82M
Employees850167
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SDGR has outperformed ZBIO by 72.6 percentage points over the past year.
  • Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
  • Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +23.29%).

About Schrodinger

SDGR stock →

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.

Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees

About Zenas BioPharma

ZBIO stock →

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.

Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees

SDGR vs ZBIO FAQ

Which is bigger, Schrodinger or Zenas BioPharma?

Schrodinger (SDGR) is larger, with a market capitalization of $1.72B compared with $1.62B for Zenas BioPharma (ZBIO).

Which stock has performed better over the past year, SDGR or ZBIO?

SDGR returned +39.22% over the past 12 months, compared with -33.38% for ZBIO (price return, excluding dividends). Past performance does not predict future results.

Are Schrodinger and Zenas BioPharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons